Dr Koen Deloose (AZ Sint-Blasius, Dendermonde, BE) discusses the 24-month outcomes of the TINTIN trial.

The trial investigates the safety and efficacy of the combination therapy with the Luminor drug-coated balloon (DCB) and the iVolution stent in the treatment of TASC C and D femoropopliteal lesions. 

 

Questions

1. What was the rationale for this trial and what guided the selection of these two products?

3. What were the key results?

4. What are the 'take-home' messages for clinicians?

5. What further research is required?

 

Recorded remotely from Dendermonde, 2021.

 

Editor: Mirjam Boros

Recording Editor: Natascha Wienand